Life Sciences
Biotech Group Pegs Drug Law's Cost at $8 Billion in Lost Funding
John Stanford of Incubate said Kendall Square still competes globally even as China's regulator cut review times to roughly 12 to 13 months.
biotech policy
Life Sciences
John Stanford of Incubate said Kendall Square still competes globally even as China's regulator cut review times to roughly 12 to 13 months.